VYNE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VYNE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-12-11), VYNE Therapeutics's share price is $2.55. VYNE Therapeutics's Tangible Book per Share of Sep. 2024 for the quarter that ended in Sep. 2024 was $4.31. Hence, VYNE Therapeutics's Price to Tangible Book Ratio of today is 0.59.
The historical rank and industry rank for VYNE Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
During the past 9 years, VYNE Therapeutics's highest Price to Tangible Book Ratio was 10.85. The lowest was 0.28. And the median was 1.18.
A closely related ratio is called PB Ratio. As of today, VYNE Therapeutics's share price is $2.55. VYNE Therapeutics's Book Value per Sharefor the quarter that ended in Sep. 2024 was $4.31. Hence, VYNE Therapeutics's P/B Ratio of today is 0.59.
The historical data trend for VYNE Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VYNE Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Price-to-Tangible-Book | Get a 7-Day Free Trial | 2.47 | 7.28 | 1.12 | 0.28 | 0.37 |
VYNE Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 1.16 | 0.37 | 0.53 | 0.38 | 0.44 |
For the Biotechnology subindustry, VYNE Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, VYNE Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where VYNE Therapeutics's Price-to-Tangible-Book falls into.
VYNE Therapeutics's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Sep. 2024 ) |
= | 2.55 | / | 4.307 | |
= | 0.59 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of VYNE Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Patrick G Lepore | director | 17-17 ROUTE 208 N, FAIRLAWN NJ 07410 |
Mutya Harsch | officer: Chief Legal Officer and GC | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Tyler Zeronda | officer: Interim CFO | C/O VYNE THERAPEUTICS, 520 U.S. HIGHWAY 22, SUITE 204, BRIDGEWATER NJ 08807 |
Andrew Saik | officer: Chief Financial Officer | 640 LEE ROAD, CHESTERBROOK PA 19087 |
Rex Bright | director | 5641 LAKE VISTA DRIVE, BONSALL CA 92003 |
Iain Stuart | officer: Chief Scientific Officer | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
David Domzalski | director, officer: President and CEO | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
Matthew T. Wiley | officer: Chief Commercial Officer | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402 |
Anthony D Bruno | director | C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866 |
Stanley Hirsch | director | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
Ilan Hadar | officer: CFO and Country Manager | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
Sharon Surrey Barbari | director | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | director, 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By Value_Insider Value_Insider • 12-12-2022
By sperokesalga sperokesalga • 05-01-2023
By sperokesalga sperokesalga • 04-19-2023
By Marketwired • 07-09-2024
By Marketwired • 09-12-2024
By sperokesalga sperokesalga • 02-10-2023
By Marketwired • 09-03-2024
By Marketwired • 05-06-2024
By Value_Insider Value_Insider • 12-02-2022
By GuruFocus Research • 11-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.